Charles River Laboratories and Medigen Vaccine Biologics are collaborating on the characterization and validation of a virus seed bank for Medigen's next-generation multivalent enterovirus vaccine. This partnership leverages Charles River's analytical platforms and expertise to accelerate vaccine development and regulatory readiness, potentially expanding future collaborations.
Charles River Laboratories and Medigen Vaccine Biologics are partnering to advance Medigen's next-generation multivalent enterovirus vaccine. Charles River will provide its advanced analytical capabilities, including Next-Generation Sequencing (NGS), to support critical Chemistry, Manufacturing, and Controls (CMC) activities. This collaboration is significant for Medigen as it aims to accelerate development, enhance global regulatory readiness, and support IND-enabling non-clinical studies for its vaccine, building on its prior success in Taiwan and Vietnam. For Charles River, it represents a new revenue stream and reinforces its position as a leading provider of biologics testing and non-clinical development services, with potential for further collaborations in other vaccine programs. The short-term impact is likely moderate, but the long-term opportunity lies in the potential for expanded partnerships and successful vaccine development, addressing unmet medical needs.